Studied in people
There are published studies in people. It is not a licensed medicine in the United States or the European Union.
This page is a stub
The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.
How strong is the evidence
How far it has climbed
Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.
- Licensed medicine
A regulator has reviewed the trials and licensed it for a named use.
- Phase 3
Large randomized trials, often thousands of people, against placebo or a standard treatment.
- Phase 2
Mid-sized trials that measure dose against effect in people with the condition.
- Phase 1 and early human studies: TB-500
First studies in people: safety, and how the body handles it.
- Cells and animals
Laboratory and animal work. An animal result is not a result in people.
- 628
- papers on PubMed
- 345
- of them in people
- 3
- randomized trials
- 70
- reviews
A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16
Handling and reconstitution
From powder to a measured sample
The same four steps for any lyophilized vial. Laboratory handling, not use in a person.
1. Read the vial
The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.
2. Add the diluent
A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.
3. Work out the strength
Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.
4. Measure the sample
Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.
The calculator below does the arithmetic and shows its working.
As powder
General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.
In solution
Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.
This is general practice for lyophilized peptides, not data on TB-500 itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage
Reconstitution calculator
Opens on vial sizes common for research peptides. Change any number. How the arithmetic works
Draw to
10 units
0.1 mL on a U-100 syringe
- Concentration
- 2.5 mg/mL
- Each unit holds
- 25 mcg
- Samples in the vial
- 20
- Sample
- 250 mcg
5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of TB-500; no amount here is a recommendation.
TB-500: on PubMed
What PubMed held for TB-500 on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.
- 628
- papers
- 345
- in humans
- 4
- clinical trials
- 3
- randomized trials
Most relevant on PubMed
Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.
- Logistic regression analysis of environmental and other variables and incidences of tuberculosis in respiratory patients
TrialPathak AK, Sharma M, Katiyar SK, et al. Scientific reports, 2020. PMID 33318598
- Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing
Randomized trialGuarnera G, DE Rosa A, Camerini R Annals of the New York Academy of Sciences, 2007. PMID 17495250
- A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers
Randomized trialRuff D, Crockford D, Girardi G, et al. Annals of the New York Academy of Sciences, 2010. PMID 20536472
- The effect of thymosin treatment of venous ulcers
Randomized trialGuarnera G, DeRosa A, Camerini R, et al. Annals of the New York Academy of Sciences, 2010. PMID 20536470
- beta-Thymosins
ReviewHannappel E Annals of the New York Academy of Sciences, 2007. PMID 17468232
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
ReviewMendias CL, Awan TM Sports medicine (Auckland, N.Z.), 2026. PMID 41966639
- Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids
StudyZeng PM, Sun XY, Li Y, et al. Stem cell reports, 2025. PMID 40816274
- Thymosin β4 Promotes Dermal Healing
ReviewKleinman HK, Sosne G Vitamins and hormones, 2016. PMID 27450738
Search used: ("thymosin beta-4"[tiab] OR "thymosin beta 4"[tiab] OR "TB-500"[tiab]). Run it on PubMed
Research links
- PubMed (opens in a new tab)Every indexed paper, newest first
- ClinicalTrials.gov (opens in a new tab)Registered trials and their status
- Europe PMC (opens in a new tab)Full text where it is open access
- Google Scholar (opens in a new tab)Papers, preprints and who cites them
- PubChem (opens in a new tab)Structure, identifiers and properties
- YouTube (opens in a new tab)Talks and lectures. Check who is speaking
These open a search for TB-500 on each site. The wiki has not reviewed what they return: a video or a preprint is not a peer-reviewed result, and none of it is medical advice.
Also in Repair and recovery
Sold in blends: BPC-157 + TB-500, BPC-157 + TB-500 + GHK-Cu, BPC-157 + TB-500 + GHK-Cu + KPV